APR 24, 2018 6:15 AM PDT

A Vaccine for Bath Salts Abuse

WRITTEN BY: Kara Marker

You may think of crystal meth when you read “the poor man’s cocaine,” but bath salts are another drug that people turn to when they can’t afford crack. A new University of Arkansas for Medical Sciences study shows the possibility for a vaccine to prevent recovering drug users of bath salts from experiencing a relapse.

Bath salts, also known as synthetic cathinones, are a type of “new psychoactive substance” (NPS) of concern to public health officials. Natural cathinone comes from the khat plant from East Africa and southern Arabia, where natives chew the leaves to experience the stimulant effects from the drug. Synthetic versions of cathinone are particularly dangerous though, because they are much more potent than the naturally occurring version.

Synthetic cathinones come in the form of white or brown crystal-like powder, marketed as a less expensive version of stimulants like methamphetamine and cocaine. The drug can be swallowed, snorted, smoked, or injected. Like other drugs, abuse of synthetic cathinones includes the risk of overdose and life-threatening side effects like organ failure. The new vaccine could block the effect of synthetic cathinones on the brain, helping recovering drug users during a relapse.

"Because the chemical structures of these illegal drugs are often changed to evade drug laws, we decided it was important to develop a single vaccine that will be effective against more than one medically dangerous synthetic cathinone," explained doctoral student Samantha McClenahan.

The vaccine targets two synthetic cathinones: methylenedioxypyrovalerone (MDPV) and alpha-pyrrolidinovalerophenone (alpha-PVP). In a rodent model of drug abuse, the vaccine successfully triggered the production of antibodies that attach to MDPV and alpha-PVP in the blood stream. This attachment decreases the stimulant effects of MDPV for months compared to unvaccinated rats.

McClenahan and others are hoping to create a vaccine that reduces the stimulant effects of the drug for at least six months, preferably up to one year to be used as a “long-lasting aid to the rehabilitation process.” Researchers will also study further the vaccine’s ability to prevent MDPV from infiltrating the brain and heart to simultaneously prevent the drug’s stimulant effects and potentially lethal side effects.

"It would likely help reduce drug concentrations in critical organs and reduce or eliminate the rewarding effect of the drug,” McClenahan said. “This could improve the chances of an individual remaining in rehabilitation treatment, which might increase the likelihood of a successful outcome."

Sources: National Institute on Drug Abuse, Experimental Biology 2018

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
APR 23, 2020
Immunology
COVID "Immunity Passports" Are a No-Go
APR 23, 2020
COVID "Immunity Passports" Are a No-Go
  Authorities are caught between dealing with the competing urgencies of abating the COVID-19 health crisis and the ...
MAY 19, 2020
Drug Discovery & Development
COVID-19 Vaccine On Track for Late 2020
MAY 19, 2020
COVID-19 Vaccine On Track for Late 2020
Moderna, a biotechnology company based in Massachusetts, has released information on its vaccine against COVID-19 from i ...
MAY 16, 2020
Neuroscience
Stem Cell Method (Parkinson's) Could Avoid Transplant Rejection
MAY 16, 2020
Stem Cell Method (Parkinson's) Could Avoid Transplant Rejection
Researchers at McLean Hospital and Massachusetts General Hospital (MGH) have tested a stem cell treatment method that av ...
MAY 26, 2020
Drug Discovery & Development
Everyone Can Produce Antibodies Against COVID-19
MAY 26, 2020
Everyone Can Produce Antibodies Against COVID-19
Researchers at Rockefeller University in New York have found that most people exposed to COVID-19, and who experience sy ...
JUL 13, 2020
Drug Discovery & Development
Russia Completes First Human Trial for COVID-19 Vaccine
JUL 13, 2020
Russia Completes First Human Trial for COVID-19 Vaccine
The Sechenov University Center for Clinical Research in Moscow, Russia, has completed its first round of clinical trials ...
JUL 15, 2020
Immunology
Immune Memory to Thwart Recurring Cancer
JUL 15, 2020
Immune Memory to Thwart Recurring Cancer
Preventing cancer from returning in the body is an integral part of any anti-cancer treatment plan. New discoveries from ...
Loading Comments...